With the CHS-114 data set to debut at SITC 2025, spotlighting its cytolytic anti-CCR8 mechanism and early immune remodeling signals, Coherus Oncology Inc. (CHRS) is aligning scientific visibility with commercial expansion. LOQTORZI continues to gain traction in nasopharyngeal carcinoma, and with trial readouts expected in 1H 2026 and Q3 earnings due November 6, the company is entering a catalyst-heavy stretch that could reshape its immuno-oncology footprint.
CHS-114 Spotlight
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com